🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🆕 #ASCO25 🆙 ☑️#LCSM Poster 🔥Dynamic changes in target protein exp. following Tx in NSCLC: Simultaneous evaluation of MET, TROP2, HER2, B7-H4, and MDM2 in paired biopsies 🎙️ Dr. Saori Murata Hidehito HORINOUCHI 📌Poster Bd71, Abstr 8591 OncoAlert ASCO meetings.asco.org/2025-asco-annu…

NeoADAURA, Osi/osi-chemo/chemo neoadj 2 vs 8% PD rate MPR 26 vs 25 vs 2%: benefit across genotype & stage. Greater depth response by osi-chemo>osi Nodal downstaging in both osi arms Osi/osi-chemo reduces PD, gets MPR Impressive EFS by MPR vs not #ASCO25

Key diagnostic cytological features of lung small cell carcinoma: -Chromatine: fine & dark - Nucleoli: absent or inconspicuous -Cytoplasm: scant Bonuns: nuclear molding, crush artifact, apoptotic cells, blue bodies, necrosis, 🔬💯🫁 👇

ERJ Open Research: Variants of SFTPA1 and SFTPA2 are involved in interstitial lung disease and lung cancer. Penetrance for the first event is 50% at 60 years old, rising to 89.3% at 80. Penetrance for lung cancer reached 50% at age 80, earliest case diagnosed at age 30.

#Lungcancer in never-smokers is rising but Europe’s screening policies still focus almost entirely on age & smoking history. That’s leaving thousands invisible to early detection. bbc.com/future/article… We need screening policies that reflect real-world risk, not just smoking

🆕article in press: DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer annalsofoncology.org/article/S0923-… Mark Awad Biagio Ricciuti, MD, PhD

FDA grants breakthrough designation to YL201 for #SCLC. YL201 is a B7-H3 directed ADC with a proprietary topoisomerase-1 inhibitor payload. Looking forward to more data from the ongoing trials. medilinkthera.com/news-details/48

C’est parti pour la réunion plénière du GFPC , à Marseille cette année !!! chantal decroisette Charles Ricordel Florian Guisier Pascale Tomasini roland schott

Merci Fabrice Barlesi pour ta très belle conférence sur les mécanismes de résistance à l’immunothérapie au cours de la réunion plénière du GFPC à Marseille ! Pascale Tomasini

Dr. Anjali Rohtagi discusses the ongoing trial utilizing sacituzumab govitecan in advanced thymoma and thymic carcinoma at Georgetown University and Stanford Medicine under PI Dr. Chul Kim . Shout out to Dr. Heather Wakelee as site PI. #DAVALung #HawaiiiLung25 #thymsm ITMIG Society

Dr. Chul Kim highlights 1L carbo+pac+rami in thymic carcinoma as the new standard of care. While some data for use of chemoIO upfront, high rates here of immune related adverse events! Heather Wakelee #DAVALung #HawaiiiLung25 #thymsm ITMIG Society

Je ne sais pas 🤷🏽‍♀️but I don’t find this doubling in #lungcancer overall survival from 8.5 mos to 20.7 mos in the last 20 yrs in 🇫🇷 still enough progress to celebrate. ➡️However, it highlights that effective systemic targeted therapy and immunotherapy can move the needle for

2/📉 CRS incidence dropped to 10% with a single pre-step-up dose of tocilizumab (8 mg/kg). ✅ 10 of 12 CRS cases were Grade 1 ❌ No Grade ≥3 CRS ❌ No repeat tocilizumab or steroid needed ➡️ Compared to ~36–58% CRS in registrational trials, this is remarkable. #mmsm #MedEd

💡Starting out in thoracic oncology? The IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders JTO & JTO CRR OncoAlert #LCSM jto.org/article/S1556-…

People with #lungcancer & low BMI are more likely to develop brain metastases - a link not seen in other cancers. New open access study in Nature Communications, July 2025. Researchers suggest it’s driven by brain signalling changes, not just weight loss. 🔗

❄️Winter of cancer immunotherapy is here. 𝐀𝐥𝐥-𝐜𝐨𝐦𝐞𝐫𝐬 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 & 𝐍𝐞𝐭𝐰𝐨𝐫𝐤-𝐞𝐟𝐟𝐞𝐜𝐭 slowed progress-we’ve hit a plateau. Time to prioritize innovation over convention! Editorial out in JTO & JTO CRR bit.ly/4eEVcv4 Fabio Salomone Antonio Nuccio

Isabelle Beuchat: ICANS is not the only neurotoxicity with T-cell engagers Data from CAR-T also shows TIAN and MNTs

🚨 Nadunolimab + Platinum Doublet Shows Promising Activity in 2L NSCLC Post-ICI 🧬💥 🔬 Study Focus: Nadunolimab, an anti-IL1RAP monoclonal antibody, was evaluated with platinum-doublet chemotherapy in advanced NSCLC (1L and 2L post-pembrolizumab) in a phase I/II study

🚨 Poste toujours disponible même sur une plus courte durée ! Pérennisation du poste possible par la suite malgré retour du congé maternité ‼️

Non-cystic fibrosis (CF) bronchiectasis is a chronic lung condition that typically causes cough and sputum production. Learn more in this Review. ja.ma/4kJZOBi